82 citations
,
March 2013 in “PLoS ONE” In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.
21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.
11 citations
,
October 2021 in “Orphanet journal of rare diseases” This study found that patients with RASopathies have lower serum IgA and CD8 levels compared to controls, indicating a potential risk for developing autoimmune disorders.
4 citations
,
October 2013 in “PLoS ONE” This study found that Vemurafenib led to a broad range of cutaneous side effects in nearly all patients with advanced melanoma, highlighting the need for regular dermatologic management and UV protection.
March 2021 in “Research Square (Research Square)” This study found that patients with RASopathies demonstrated lower levels of serum IgA and CD8 T cells compared to controls, potentially indicating an increased risk of developing autoimmune disorders.